<DOC>
	<DOCNO>NCT01220531</DOCNO>
	<brief_summary>Complete DiGeorge anomaly ( cDGA ) disorder thymus function . With thymus function , bone marrow stem cell develop T cell , fight infection . Complete DiGeorge anomaly patient fight infection immunodeficient . Without successful treatment , cDGA patient usually die age 2 year . Thymus transplantation without immunosuppression ( drug give transplantation ) result development good T cell function complete DiGeorge anomaly subject . This Phase I/II study continue thymus transplantation safety efficacy research treatment complete DiGeorge anomaly . Eligible participant undergo thymus transplantation biopsy . Immune function test continue one year post-transplantation .</brief_summary>
	<brief_title>Thymus Transplantation Safety-Efficacy</brief_title>
	<detailed_description>Complete DiGeorge anomaly ( cDGA ) congenital disorder characterize athymia . Without successful treatment , child remain immunodeficient usually die age 2 year . In complete DiGeorge subject , thymus transplantation without immunosuppression result diverse T cell development good T cell function . The purpose Phase I/II study continue thymus transplantation safety efficacy research treatment complete DiGeorge anomaly . Until thymus transplantation FDA approve standard care DiGeorge anomaly , research study participation mean patient may access potentially life-saving procedure . This protocol include 4 group : one subject require immunosuppression ; 3 immunosuppression group subject different T cell function level suppress adequately . Eligible subject undergo thymus transplantation allograft biopsy . Protocol specify study continue approximately one year post-transplantation . Study participation last two year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>DiGeorge Syndrome</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Transplant Inclusion : Must 1 following : 22q11 10p13 hemizygosity ; hypocalcemia require replacement ; congenital heart disease ; CHARGE association CHD7 mutation Complete DiGeorge : &lt; 50 CD3+ T cells/cumm &lt; 50 CD3+ T cells/cumm CD62L+ CD45RA+ , &lt; 5 % CD3+ cell CD62L+ CD45RA+ Atypical DiGeorge must , , rash . Group 1 •Typical cDGA whose T cell PHA response &lt; 5,000 cpm &lt; 20 fold PHA response . Group 2 •Typical cDGA whose T cell PHA response &gt; 5,000 cpm &lt; 50,000 cpm &gt; 20 fold PHA response Group 3 Typical cDGA whose T cell PHA response &gt; 50,000 cpm Typical cDGA maternal engraftment Atypical cDGA whose T cell PHA response &lt; 40,000 cpm immunosuppression &lt; 75,000 cpm PHA immunosuppression Atypical cDGA group 3 PHA response &amp; maternal engraftment Group 4 Atypical cDGA PHA responses &gt; 75,000cpm immunosuppression PHA responses &gt; 40,000cpm immunosuppression Atypical cDGA maternal engraftment group 4 PHA response Transplant Exclusion : Heart surgery &lt; 4 wks pretransplantation Heart surgery anticipate w/in 3 month propose transplantation Rejection surgeon anesthesiologist surgical candidate Lack sufficient muscle tissue accept transplant 4 grams/m2 body surface area HIV infection Prior attempt immune reconstitution , bone marrow transplant previous thymus transplant CMV 2 test Groups 2 , 3 , 4 Biological Mother Inclusion/Exclusion : • Must biological mother thymus recipient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>DiGeorge Anomaly</keyword>
	<keyword>Thymus Transplantation</keyword>
	<keyword>DiGeorge Syndrome</keyword>
	<keyword>Athymia</keyword>
	<keyword>Low T cell number</keyword>
	<keyword>Immunoreconstitution</keyword>
	<keyword>Immunodeficiency</keyword>
	<keyword>Complete DiGeorge</keyword>
	<keyword>Typical DiGeorge</keyword>
	<keyword>Atypical DiGeorge</keyword>
	<keyword>Complete DiGeorge Anomaly</keyword>
</DOC>